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ABSTRACT 30 
Background: Type 3 innate lymphoid cells (ILC3s) are involved in the maintenance of 31 
mucosal homeostasis; however, their role in immunoregulation has been unknown. Immature 32 
transitional regulatory B
 
(itBreg) cells are innate-like B cells with immunosuppressive 33 
properties, and the in vivo mechanisms by which they are induced have not been fully 34 
clarified.  35 
Objective: We aimed to investigate the ILC3-B cell interaction that probably takes place in 36 
human tonsils. 37 
Methods: ILC3s were isolated from peripheral blood and palatine tonsils, expanded and 38 
cocultured with naïve B cells. Tonsillar ILC3s and Breg cells were visualized with 39 
immunofluorescence histology. The frequencies of ILC3s were measured in tonsil tissue of 40 
allergic and non-allergic patients; and in peripheral blood of allergic asthmatics and healthy 41 
controls. 42 
Results: A mutually beneficial relationship was revealed between ILC3s and B cells: ILC3s 43 
induced IL-15 production in B cells via BAFF-receptor, while IL-15, a potent growth factor for 44 
ILC3s, induced the expression of CD40L on circulating and tonsillar ILC3s. IL-15-activated 45 
CD40L+ILC3s helped B cell survival, proliferation and the differentiation of IL-10-secreting, 46 
functional itBreg cells in a CD40L- and BAFF-receptor-dependent manner. ILC3s and Breg cells 47 
were in close connection with each other in palatine tonsils. The frequency of ILC3s was 48 
reduced in tonsil tissue of allergic patients and in peripheral blood of allergic asthmatics. 49 
Conclusion: Human CD40L+ILC3s provide innate B cell help, and are involved in an innate 50 
immunoregulatory mechanism by the induction of itBreg cell differentiation, which takes place 51 
in palatine tonsils in vivo. This mechanism may contribute to the maintenance of the immune 52 
tolerance and become insufficient in allergic diseases. 53 
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KEY MESSAGES 55 
• CD40L-expressing, activated ILC3s provide innate B cell help in tonsils, and induce IL-56 
10-producing, PD-L1-expressing, functional Breg cells with an immature transitional 57 
phenotype. 58 
• ILC3s and B cells communicate with each other via CD40L, B cell-activating factor and 59 
IL-15. 60 
• The frequency of ILC3s is reduced in tonsil tissue of allergic patients and in peripheral 61 
blood of allergic asthmatics. 62 
 63 
CAPSULE SUMMARY 64 
ILC3-mediated induction of Breg cells is a novel, innate immunoregulatory mechanism that 65 
may contribute to the maintenance of immune tolerance and become insufficient in allergy, 66 
as the frequency of ILC3s is reduced in allergic diseases. 67 
 68 
Key words: Type 3 innate lymphoid cells, ILC3, immature transitional regulatory B cells, Breg, 69 
tonsils, allergy, asthma, IL-10, immunoregulation, immune tolerance. 70 
 71 
Abbreviations: APRIL, a proliferation-inducing ligand; BAFF, B cell-activating factor; BAFFr, 72 
BAFF-receptor; Breg cell, regulatory B cell; cNK cell, conventional NK cell; GINA, Global 73 
Initiative for Asthma; ILC, innate lymphoid cell; ILC3, type 3 innate lymphoid cell; itBreg cell, 74 
immature transitional regulatory B cell; L cell, human CD40L-expressing mouse fibroblast; 75 
mDC, myeloid dendritic cell; MFI, median fluorescence intensity; NK cell, natural killer cell; 76 
PBMC, peripheral blood mononuclear cell; PD-L1, programmed death-ligand 1; RORγt, 77 
Retinoic acid receptor-related orphan receptor-γt; SEM, standard error of the mean; TMC, 78 
tonsillar mononuclear cell; Treg cell, regulatory T cell. 79 
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INTRODUCTION 81 
The exploration of the diversity of innate lymphoid cells (ILCs)1-2 and “innate-like” B cell 82 
subsets with regulatory potential3 has substantially redrawn the picture of immune 83 
homeostasis and tissue inflammation. Despite detailed descriptions of the mechanisms by 84 
which ILC subsets contribute to various adaptive and innate immune processes2, 4, their 85 
involvement in immunoregulation has not been delineated yet. Retinoic acid receptor-related 86 
orphan receptor-γt (RORγt)-expressing type 3 ILCs (ILC3s) in adult mice and humans play a 87 
role in the innate immune defense at the mucosal barrier surfaces5 and tissue regeneration 88 
after damage6-9; mainly via secretion of their signature-cytokine IL-2210-12. ILC3s are also 89 
involved in limitation of pathological adaptive immune responses against commensal bacteria 90 
in the gut13. Thus, ILC3s have a dedicated role in maintenance and restoration of 91 
homeostasis at the interface of the environment and the body4.  92 
Among the several B cell subsets with immunoregulatory properties that have been 93 
identified14, there is an immature transitional regulatory B (itBreg) cell subpopulation with 94 
CD19+CD27–IgD+IgM+CD24highCD38highCD1dhigh phenotype and IL-10-producing capacity15. 95 
The in vivo differentiation pathway of itBreg cells has not been fully explored so far14. 96 
It has recently been shown that ILCs can have an influence on antibody production in 97 
mice16-17 and splenic ILC3s stimulate marginal zone B cells via CD40L (CD154) and B cell-98 
activating factor (BAFF), and help to orchestrate innate-like IgM antibody production in 99 
humans18, suggesting that a functional ILC-B cell interaction takes place in vivo. 100 
The present study describes that CD40L+ILC3s reside on the border of the T cell - B 101 
cell areas in tonsils, and are in close contact with B cells in vivo. CD40L+ILC3s and B cells 102 
are in mutually beneficial relationship with each other, as CD40L+ILC3s strongly support 103 
survival and proliferation of the B cells, promote IgM secretion and IL-10-producing, 104 
programmed death-ligand 1 (PD-L1)-expressing itBreg cell differentiation in a CD40L- and 105 
BAFF-dependent manner, while B cells upregulate IL-15, a growth factor for ILC3s, upon 106 
interaction with CD40L+ILC3s. ILC3s may contribute to the maintenance of the immune 107 
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tolerance via induction of itBreg cells. A relative deficiency of ILC3s in allergic diseases is 108 
demonstrated. 109 
 110 
MATERIALS AND METHODS 111 
Peripheral blood and tonsil tissue samples 112 
Peripheral blood samples for in vitro cell culture experiments were collected from healthy 113 
volunteers. 114 
Human palatine tonsil tissue samples of eight allergic and eleven non-allergic patients 115 
were obtained from hospitals of Davos and Chur, Switzerland. Patients underwent elective 116 
tonsillectomy because of hypertrophic and obstructive tonsils. Patients with clinical history of 117 
atopic dermatitis, food allergy or allergic asthma, together with skin prick test or specific IgE 118 
positivity were included in the allergic group. Only the samples of non-allergic patients were 119 
used for in vitro ILC3 and B cell coculture experiments. The prevalence of ILC3s and the 120 
IL15 mRNA expression of the B cells upon in vitro stimulation were compared between 121 
samples of allergic and non-allergic donors.  All donors were free of any current infection. 122 
Forty-one adult, partly controlled, non-obese (BMI < 30), allergic eosinophilic asthma 123 
patients (Global Initiative for Asthma – GINA treatment Step 3 to 4) were included in the 124 
study at their arrival to the hospital (Hochgebirgsklinik, Davos-Wolfgang, Switzerland), before 125 
the introduction of any new medication, or starting of the rehabilitation program. The patients 126 
had atopy (positive skin prick test or specific IgE) and the asthma symptoms were related to 127 
the relevant allergen (e.g. exacerbated in pollen season; reduced in house dust mite free 128 
environment). All patients were on medium- or high-dose inhaled corticosteroid and long-129 
acting β2-agonist treatment and have not received systemic glucocorticoids in last 4 month. 130 
Patients that fulfill these inclusion criteria were selected by a pulmonologist. Twenty-three 131 
age-matched healthy volunteers served as controls for comparison of circulating ILC3 levels. 132 
All sample preparation and analyses were performed within 3 hours of blood withdrawal. The 133 
leftover of the PBMC samples that were not used up for the experiments, were frozen and 134 
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stored in biobank. Therefore, altogether 17 healthy and 17 allergic asthmatic samples were 135 
available for the later performed itBreg and Treg cell measurements. 136 
The study was approved by the Cantonal Ethics Committee of Graubünden, and 137 
informed consent was obtained from all donors. 138 
 139 
Flow cytometry and cell sorting 140 
Flow cytometry data were acquired on Galios (Beckman Coulter), FACS Aria II (Aria III 141 
upgrade) and LSRFortessa (Beckton Dickinson) instruments, and were analyzed with Kaluza 142 
software (Beckman Coulter). In order to improve the efficiency of ILC3 sorting, the peripheral 143 
blood mononuclear cell (PBMC) samples were first depleted of monocytes, T cells and B 144 
cells and TMC samples were depleted of B cells. For this purpose, the cells were labeled 145 
with magnetic microbead-bound anti-CD14, anti-CD3 and anti-CD19 antibodies (or just with 146 
anti-CD19 antibodies for TMCs) and the positive cell populations were depleted by 147 
immunomagnetic separation (AutoMACS, Miltenyi Biotec). We used the remaining cells for 148 
ILC3 sorting. Lineage markers (Lin) were CD3, CD19, CD20, CD14, CD34, CD11c, CD94 for 149 
ILC3 sorting experiments. Before naïve B cell sorting, monocytes and T cells were depleted 150 
from the samples. ILC3s and naïve B cells were sorted on a FACS Aria II instrument to high 151 
purity (≥98%). 152 
 153 
Establishment of CD40L+ILC3 cell line, as well as CD40L+ILC3 and B cell cocultures 154 
Sorted Lin–CD4–CD56–IL-7Rα+CD161+c-Kit+ ILC3s were expanded for 20 days with irradiated 155 
autologous PBMCs (30 Gy) and IL-15 (10 ng/mL). As IL-15 is a potent growth factor for 156 
conventional natural killer (cNK) cells19 accordingly, CD94, a characteristic C-type lectin 157 
receptor of cNK cells was used to discriminate cNK cells from other ILCs. After expansion 158 
CD94–c-KithighCD40L+ ILC3s (referred to as CD40L+ILC3s), as well as CD94–c-KithighCD40L– 159 
ILC3s (referred to as CD40L–ILC3s) and CD94+CD40L–c-Kitlow cNK cells were sorted for in 160 
vitro experiments, including CD40L+ILC3 and B cell, as well as CD40L–ILC3 and B cell 161 
cocultures. 162 
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For the tonsil-derived and blood-derived coculture experiments CD19+CD27–IgG–IgA– 163 
naïve B cells were sorted from a second blood sample of the same blood donor and another 164 
aliquot of the same TMC sample used for the initial ILC3 isolation, respectively. 165 
In the coculture experiments all conditions (CD40L+ILC3s alone, B cells alone, ILC3 + 166 
B cell cocultures, T + B cell cocultures and B + L cell cocultures) were initially stimulated with 167 
synthetic phosphorothioate B type CpG 2006 oligodeoxynucleotide (Microsynth; 1 µM) and 168 
cultured with IL-15 (10 ng/mL). CD40L+ILC3s and B cells were cocultured in 1:1, 1:3, 1:7 and 169 
1:15 ratios. 170 
 171 
Statistical analysis 172 
Data were analyzed in Statistica 7.0 and GraphPad Prism. Student’s t-test or one-way 173 
analysis of variance (ANOVA) with Bonferroni post hoc test were used for parametric, and 174 
Mann–Whitney U test or Kruskal-Wallis test with Dunn’s post hoc test were used for non-175 
parametric variables, as appropriate. The interrelation of the various cell populations were 176 
analyzed by Spearman's rank correlation. Sample sizes were chosen based on previous 177 
studies. The only reason for data exclusion was the technical error of the cell culture. All 178 
results are expressed as means±SEM. 179 
 180 
Further details of the methods are described in Online Repository. 181 
 182 
RESULTS 183 
Type 3 innate lymphoid cells of peripheral blood and tonsil tissue acquire CD40L-184 
expression in response to IL-15 185 
IL-15 is known to induce ILC proliferation2, 20, however its role in ILC3 activation and 186 
differentiation has not been clear so far. Therefore, as a novel approach, we expanded ILC3s 187 
with IL-15 (for 20 days). Blood-derived ILC3s differentiated into 3 major cell populations upon 188 
IL-15 stimulation (Fig 1, A): CD94+CD40L–c-Kitlow conventional natural killer (cNK) cells, 189 
CD94–CD40L–c-Kithigh ILC3s (referred to as CD40L–ILC3s) and CD94–CD40L+c-Kithigh ILC3s 190 
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(referred to as CD40L+ILC3s). Tonsillar ILC3s, however, had much less capacity to 191 
differentiate into cNK cells; whereas abundant CD40L–ILC3, as well as CD40L+ILC3 192 
populations developed in these cultures (Fig 1, B). 193 
ILC3s are CD45+ cells of hematopoetic origin, consequently migrate from the bone 194 
marrow to secondary lymphoid organs and mucosa-associated lymphoid tissues through the 195 
blood-stream. ILC3s represent a rare cell subset both in the blood and in palatine tonsils 196 
(Non-allergic and Healthy groups in Fig 8, B and C, respectively). Lin–CD4–CD56–IL-197 
7Rα+CD161+c-Kit+ ILC3s (Fig E1, A and B) were sorted and expanded for in vitro functional 198 
experiments. Freshly isolated ILC3s expressed high levels of RORC mRNA encoding 199 
RORγt, the signature transcription factor of the ILC3s (Fig E1, C).  200 
Tonsillar epithelial cells and myeloid dendritic cells (mDCs) expressed high levels of 201 
IL15 mRNA (Fig 1, C), they can be the local sources of this growth factor for ILC3s. 202 
Circulating ILC3s did not express natural killer receptor NKp44 (CD336) on their surface. 203 
Whereas primary tonsillar ILC3s were predominantly NKp44+, blood-derived ILC3s acquired 204 
this mucosal phenotype in response to IL-15 (Fig 1, D).  205 
In the next step, we aimed to determine the key characteristics of CD40L+ILC3s in 206 
order to provide evidence that they are indeed in the ILC3 lineage.  First, CD40L+ILC3s 207 
expressed high level of RORC mRNA (Fig 1, E), as well as RORγt protein (Fig 1, F). 208 
Second, CD40L+ILC3s secreted high amounts of IL-22 in response to IL-23 (Fig 1, G); and 209 
third, CD40L+ILC3s did not express GATA3 mRNA (Fig E2, A) or TBX21 mRNA (encoding 210 
T-bet; Fig E2, B), representing the characteristic transcription factors of ILC2s and ILC1s, 211 
respectively2. In addition, tonsillar ILC3s expressed the mRNA encoding CD40L (CD40LG) 212 
directly after isolation of cells, without any culture (Fig 1, H) and CD40L protein was also 213 
shown on the surface of ILC3s ex vivo (Fig 1, I). CD40L+ILC3s, did not express granzyme B 214 
or perforin, the characteristic cytotoxic enzymes of cNK cells (Fig E2, C and D).  215 
 216 
CD40L+ILC3s are residing at the interface between T cell and B cell areas in palatine 217 
tonsils and support B cell survival, proliferation and differentiation 218 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
9 
 
Our next focus was to delineate the in vivo function of CD40L+ILC3s. The anatomical 219 
localization of CD40L+ILC3s in human palatine tonsils has implications on their functional 220 
properties. ILC3s typically reside in the interfollicular area in secondary lymphoid organs13. 221 
Besides Th17 cells, only ILC3s express RORγt in tonsil tissue. Therefore we visualized with 222 
immunofluorescence histology that RORγt+CD3– ILC3s were particularly localized at the 223 
interface between T cell and B cell areas in tonsils; and were in close contact with CD20+ B 224 
cells (Fig E3). CD40 is constitutively expressed on the surface of B lymphocytes. Its 225 
interaction with CD40L is crucial for the induction of B cell proliferation and differentiation, 226 
and also essential for their long term survival. CD40L-expressing CD161+ ILCs were 227 
visualized with immunofluorescence histology, and were localized in the proximity of CD20+ B 228 
cells in tonsils (Fig E4). 229 
Considering the localization of the CD40L+ILC3s in tonsils (Fig E3), it can be 230 
expected that the interaction of CD40L+ILC3s and B cells takes place in vivo. CD40L+ILC3s 231 
(as well as CD40L–ILC3s) express toll-like receptor 9 (TLR9; Fig E5, A), thus, ILC3s and B 232 
cells21 are both able to respond to unmethlyated CpG oligodeoxynucleotides. CD40L can be 233 
cleaved from the cell surface and released by CD40L+ cells, such as activated T helper cells. 234 
The soluble form of CD40L (sCD40L) has similar B cell-stimulatory effect to membrane-235 
bound CD40L22. CD40L+ILC3s also released sCD40L, and this was further enhanced by 236 
CpG (Fig E5, B), while the surface expression of CD40L did not change in response to CpG 237 
stimulation (Fig E5, C). 238 
In order to investigate ILC3-B cell interaction in detail, we cocultured CD40L+ and 239 
CD40L–ILC3s with B cells. We used autologous, CD19+CD27–IgA–IgG–IgD+IgM+CD38+ naïve 240 
B cells of high purity (Fig E6 A and B). This B cell pool includes both immature transitional 241 
and mature naïve B cells15, 23. We demonstrated that both blood- and tonsil-derived 242 
CD40L+ILC3s supported B cell survival and proliferation in a dose-dependent manner (Fig 2, 243 
A-C and 3, A and B, respectively). IgM production was also strongly induced by 244 
CD40L+ILC3s in cocultures. This effect was specifically attributable to ILC3s, as CD40L 245 
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stimulation solely, provided by L cells (irradiated, human CD40L-expressing mouse 246 
fibroblasts), was not sufficient to induce high IgM production (Fig 2, D). 247 
 248 
CD40L+ILC3-mediated innate B cell help is specifically focused on immature 249 
transitional B cells 250 
The characterization of viable B cells in the cocultures demonstrated which subset is the 251 
preferred target of CD40L+ILC3-mediated help. CD40L+ILC3 and B cell cocultures were 252 
found to be considerably enriched in CD19+CD27–IgD+IgM+CD24highCD38highCD1dhigh 253 
immature transitional B cells (itB cells defined in Fig 4, A). The itB cells were also 254 
proliferating in these cocultures, although slower than IgM single-positive B cells (Fig 4, B). 255 
In CD40L+ILC3 cocultures, there was a small, but significant increase in the relative 256 
abundance of itB cells already on day 6 compared with CD40L–ILC3 cocultures, L cell 257 
cocultures and B cells alone; and this difference became prominent on day 12 (Fig 4, C). 258 
CD40L+ILC3s efficiently supported the long-term survival of itB cells, while L cells failed to 259 
exert the same effect. CD138+ B cells were not detectable on day 12 in the CD40L+ILC3 and 260 
B cell cocultures. In summary, these data demonstrate that CD40L+ILC3s provided innate, T 261 
cell-independent help to itB cells. The presence of itB cells in tonsillar mononuclear cells 262 
(TMCs) was confirmed right after isolation, without any in vitro stimulation or cell culture (Fig 263 
4, D). 264 
 265 
CD40L+ILC3s induce the development of IL-10-secreting PD-L1+Breg cells  266 
The secretion of IL-10, IL-1ra and IL-6 dose-dependently increased in parallel to the 267 
increasing proportion of CD40L+ILC3s in B cell cocultures. The balance between regulatory 268 
(IL-10, IL-1ra) and pro-inflammatory (IL-6) cytokines remarkably tilted towards the regulatory 269 
direction in CD40L+ILC3 and B cell cocultures, suggesting the development of Breg cells. In 270 
contrast, this balance rather skewed towards pro-inflammatory cytokine IL-6 in the cocultures 271 
of B cells and L cells (Fig 5, A). Our data clearly demonstrated that the IL-10-producing B 272 
cell differentiation was dose-dependently related to the relative abundance of CD40L+ILC3s 273 
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in the blood-derived cocultures (Fig 5, B) and was efficiently induced in tonsil-derived 274 
CD40L+ILC3 and B cell cocultures (Fig 3, C). 275 
Interestingly, the IL-10-producing B cells in CD40L+ILC3 and B cell cocultures were 276 
IL-6+IL-10+ on day 6, probably due to the initial CpG stimulation, however became IL-6–IL-10+ 277 
on day 12 (Fig 5, C). CD40L+ILC3s were also IL-6+ in 85.2±3.2% on day 6 and became IL-6– 278 
in 97.2±1.8% on day 12, however they did not produce significant amount of IL-10 at any 279 
time point. 280 
Further characterization of the IL-10+B cells demonstrated that on day 12 up to 45% 281 
of these cells showed a CD19+IgD+IgM+CD24highCD38high itB cell phenotype. This was 282 
observable only in CD40L+ILC3 cocultures and not in other control conditions (Fig 5, D). 283 
Considering that B cells can contact both the abundant T cells and the relatively rare 284 
ILC3s in the tissues, we aimed to examine the difference between these two interactions in 285 
order to define the specific function of CD40L+ILC3s. T cells were much weaker in the 286 
support of long term survival of itB cells compared to CD40L+ILC3s, as on day 12 a lower 287 
relative abundance of itB cells was observed both within all B cells and within IL-10+B cells in 288 
T cell and B cell cocultures compared to that of in CD40L+ILC3 and B cell cocultures (Fig 5, 289 
E). 290 
As an additional marker of regulatory phenotype, IL-10+B cells expressed PD-L1 on 291 
their surface (Fig 5, F).  292 
In order to prove that the developed IL-10+B cells were bona fide regulatory B (Breg) 293 
cells, B cells were isolated from CD40L+ILC3 cocultures on day 12 and tested in a 294 
suppression assay. CD40L+ILC3 coculture-derived Breg cells were able to suppress tetanus 295 
toxoid-induced T cell proliferation in a dose-dependent manner. Their suppressive efficiency 296 
was comparable to that of regulatory T (Treg) cells or rhIL-10 (10 ng/mL) and was dependent 297 
on IL-10 as it was inhibited by anti-IL-10-receptor blocking antibody (Fig 5, G). 298 
 299 
Role of CD40L in ILC3-B cell interaction 300 
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B cell viability, IL-10+Breg cell differentiation, both regulatory (IL-10, IL-1ra) and 301 
proinflammatory (IL-6) cytokine production and IgM secretion were strongly, and proliferative 302 
capacity was to a lesser extent dependent on ILC3-provided CD40L-mediated help. This was 303 
suggested by the observation that the absence of CD40L from the surface of ILC3s (in case 304 
of CD40L–ILC3), or the inhibition of CD40-CD40L interaction by a neutralizing anti-CD40L 305 
antibody (Fig 6, A-C), as well as the physical prevention of cell-cell contact in transwell plate 306 
cocultures (Fig 6, D-E) resulted in a reduction of the B cell-supporting effects of ILC3s. 307 
Meanwhile, the viability of ILC3s was not affected by the physical separation of B cells in 308 
transwell cocultures (Fig 6, D). Moreover, the specific itB cell-inducing effects of 309 
CD40L+ILC3s were still partially persisted even in the absence of cell-cell contact (in 310 
transwell cocultures; Fig 6, F). 311 
 312 
B cell-activating factor (BAFF) and IL-15 are key players of bilateral ILC3-B cell 313 
interaction  314 
CD40L+ILC3s were able to produce BAFF in response to IFN-γ (Fig 7, A). BAFF is a key 315 
cytokine of B cell maturation 24 and survival 25. Substantial amounts of IFN-γ are secreted 316 
spontaneously in tonsils 26, which can be further increased during immune responses against 317 
invading microorganisms (e.g. in bacterial infection) and thus, probably able to induce BAFF 318 
production in ILC3s in vivo. Moreover, B cells upregulated IL15 mRNA expression upon 319 
interaction with CD40L+ILC3s in cocultures (Fig 7, B). IL-15 production of B cells was 320 
induced only by CD40L+ILC3s (not by L cells), and was inhibited by anti-BAFF-receptor 321 
(αBAFFr) blocking antibody (Fig 7, C). The growth and survival of ILC3s depended on IL-15, 322 
as they ceased to proliferate and died off within 6 days after withdrawal of this cytokine from 323 
the culture medium (see second column in Fig 7, D). To analyze the ILC3-supporting effects 324 
of B cells, we compared ILC3 survival in ILC3 alone cultures and B cell cocultures in the 325 
presence or absence of IL-15 supplementation. ILC3 survival was significantly higher in B 326 
cell cocultures compared to ILC3 alone cultures without IL-15 (Fig 7, D). 327 
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Blocking of BAFF-receptor did not influence the B cell viability, proliferation, IL-10-328 
producing B cell differentiation, cytokine and IgM production in CD40L+ILC3 and B cell 329 
cocultures (Fig E7, A-E). However, the itB cell-inducing effects of CD40L+ILC3s were 330 
mediated – at least in part – via BAFF–BAFF-receptor interaction, as the relative abundance 331 
of itB cells was reduced by αBAFFr in cocultures (Fig 7, E). 332 
To further clarify the role of BAFF in IL-15 production, we stimulated tonsillar naïve B 333 
cells with BAFF or CpG alone, or both together. BAFF and CpG stimulation induced IL15 334 
mRNA expression (Fig 7, F) and IL-15 production (Fig 7, G) in tonsil-derived naïve B cells 335 
isolated from non-allergic patients, but was not able to induce IL-15 in B cells of allergic 336 
patients. 337 
 338 
ILC3s and IL-10+Breg cells colocalize in palatine tonsils in vivo 339 
In order to demonstrate that the above-detailed peculiar interaction of ILC3s and B cells is 340 
operational in vivo, ILC3s (RORγt+CD3–) and Breg cells (CD20+IL-10+) were visualized with 341 
immunofluorescence histology. These cells were in close contact with each other (Fig 8, A), 342 
were found in niches of regulatory cells that also harbor numerous CD3+IL10+Treg cells, and 343 
localized in the interfollicular area of palatine tonsils (Fig E8, A). 344 
 345 
The relative abundance of ILC3s is reduced in allergic diseases 346 
The relative frequency of ILC3 cell was lower in TMC lymphocytes isolated from palatine 347 
tonsil tissue of allergic compared to non-allergic patients (Fig 8, B). Both ILC3s and itBreg 348 
cells were less abundant in the peripheral blood of patients with allergic asthma compared to 349 
healthy controls (Fig 8, C and E8, B); but the Treg cells were equal in the two groups (Fig E8, 350 
C). The percentages of ILC3s positively correlated with itBreg cells (Fig 8, D); while Treg cell 351 
did not correlate with either ILC3s or itBreg cells (Fig E8, D and E). 352 
 353 
DISCUSSION 354 
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The present study provides evidence for the first time that activated, CD40L-expressing type 355 
3 innate lymphoid cells (CD40L+ILC3s) has a dedicated role in the induction of the immature 356 
transitional regulatory B (itBreg) cells. 357 
Human circulating Lin–CD4–CD56–IL-7Rα+CD161+c-Kit+ILC3s were able to 358 
differentiate into the recently identified18, activated form of ILC3s, the CD40L+ILC3, in 359 
response to IL-15. We used IL-15 to expand low numbers of ILC3s isolated either from 360 
peripheral blood or from palatine tonsil tissue samples, established CD40L+ILC3 cell lines 361 
and demonstrated their functional properties. Tonsillar epithelial cells and mDCs may 362 
contribute to the supporting microenvironment of the CD40L+ILC3s in the tissue via their IL-363 
15 production. B cells can also secrete IL-1527, and we demonstrated that BAFF, together 364 
with CpG stimulation induced IL-15 production in naïve B cells. Naïve B cells also 365 
upregulated IL-15 expression upon interaction with ILC3s, and the CD40L+ILC3-induced IL-366 
15 production was mediated by BAFF in a BAFF-receptor-dependent manner. Taken 367 
together, several lines of evidence indicate that CD40L+ILC3s and B cells are in a mutually 368 
beneficial relationship, and B cells contribute to the ILC3-supporting microenvironment in the 369 
tissues. The high expression level of NKp44 on tonsillar ILC3s also suggests that there is an 370 
IL-15-rich microenvironment in tonsils, as NKp44 is upregulated by IL-15 in blood-derived 371 
ILC3s. 372 
Without appropriate stimulation, B cell survival is very limited. However, our data 373 
clearly demonstrated that CD40L+ILC3s strongly support naïve B cell survival and 374 
proliferation in vitro. The anatomical localization of ILC3s in human palatine tonsils enables 375 
them to encounter and contact B cells in vivo. The expression of the CD40L on the surface of 376 
ILC3s makes the interaction with B cells almost self-evident, because of the well-established, 377 
essential role of CD40-CD40L interaction in B cell activation, differentiation and survival22, 28. 378 
Moreover, both ILC3s and B cells express TLR9, and we demonstrated that the release of 379 
sCD40L, and thus the B cell-fostering capacity of the CD40L+ILC3s, were increased upon 380 
stimulation with CpG. Besides CD40L expression, ILC3s are also able to produce BAFF29, 381 
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another B cell stimulating factor24. Consequently, both spatial and contextual factors suggest 382 
that ILC3-B cell interaction takes place in tonsils, in vivo. 383 
CD40L+ILC3-mediated B cell help was specifically focused on immature transitional B 384 
cells. Moreover, here we reported that CD40L+ILC3s have an extraordinary capacity to 385 
induce the development of IL-10-secreting, PD-L1-expressing, functional Breg cells. The 386 
comparison of the B cell-supporting effects of ILC3s and T cells revealed that the specific 387 
role of CD40L+ILC3s is particularly the induction of Breg cells with immature transitional 388 
phenotype (itBreg), and not only the induction Breg cells in general. The CD19+CD27–389 
IgD+IgM+CD24highCD38highCD1dhighitBreg cells23 have a remarkable immunoregulatory 390 
capacity15, 30-33, and are deficient and/or functionally impaired in autoimmune diseases (e.g. 391 
systemic lupus erythematosus15, rheumatoid arthritis32). The expression of PD-L1, an 392 
inhibitory costimulatory molecule, may also contribute to the immunoregulatory function of 393 
Breg cells34-35. 394 
Increasing evidence suggest4 that ILC3s play key role in mucosal homeostasis and 395 
immunoregulation via IL-22 production5, 8, 11-12, promotion of natural IgM secretion18, limitation 396 
of immune responses against commensal bacteria13, inhibition of Th17-mediated intestinal 397 
inflammation36 and restoration of lymphoid tissue integrity after destructive infection7; 398 
consequently, the demonstrated ability of CD40L+ILC3s to promote itBreg cell differentiation 399 
fits well to the regulatory image4 of the ILC3s. 400 
B cells are known to produce IL-6 in response to innate stimulation with CpG, and the 401 
cytokine secretion is further increased in the presence of CD40L37. These stimuli also induce 402 
the secretion of the inhibitory cytokines (IL-10 and IL-1ra), however, typically they do not 403 
reach to high levels in vitro. Here we demonstrated that CD40L+ILCs were potent inducers of 404 
cytokine-production by B cells. The seemingly contradictory activation state of the B cells (i.e. 405 
parallel production of IL-6 and IL-10) is a matter of a long-standing debate. A recent study 406 
suggested an explanation for this: IL-6 could be essential for the IL-10-producing B cell 407 
development38. Although the exact cellular sources of IL-6 have not been specified in that 408 
study, it has been shown that massive IL-6 production from mesenteric lymph node 409 
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lymphocytes and splenocytes, most probably including B cells and ILC3s, is required for 410 
normal Breg cell development. In our CD40L+ILC3 and B cell cocultures indeed both cell types 411 
were producing IL-6 in the early phase, on day 6 after activation with CpG, and this may 412 
facilitate differentiation of IL-10+IL-6– Breg cells detected on day 12. 413 
We showed that CD40-CD40L interaction plays a pivotal role in ILC3-B cell 414 
communication, as it was crucial for CD40L+ILC3-induced Breg cell development, as well as 415 
for cytokine and IgM production. ILC3-derived BAFF may also participate in itBreg cell 416 
induction in human tonsils, as it is an important cytokine of the ILC3-B cell interplay. BAFF 417 
participates in T cell-independent help provided by DCs, macrophages, neutrophils and 418 
ILC3s to splenic marginal zone B cells and plasma cells18, and it is known to induce IL-10-419 
producing Breg cells in mice39. CD40L+ILC3s could produce BAFF, however we could not 420 
detect a proliferation-inducing ligand (APRIL) in these cells. We observed that CD40L+ILC3s 421 
exerted an itB cell-inducing effect even in the absence of cell-cell contact (in transwell 422 
cocultures), consequently this can be partially mediated by soluble factor(s) including BAFF. 423 
BAFF signaling via BAFFr (TNFRSF13C) has a key role in B cell maturation, as transitional, 424 
follicular and marginal zone B cells numbers are strongly reduced in BAFFr-deficient mice40. 425 
We found that itB cell-inducing effect of ILC3s was also BAFF-dependent, as it was reduced 426 
by neutralization of BAFF-receptor. 427 
Tonsils have been identified as important mucosal sites of immune tolerance41, where 428 
the generation of functional allergen-specific Treg cells occurs. We demonstrated that indeed 429 
RORγt+CD3– ILC3s and CD20+IL-10+Breg cells colocalized in the palatine tonsils in vivo, they 430 
contacted each other, and were in the same regions as CD3+IL-10+Treg cells. The data 431 
suggest that there are regulatory niches in tonsils where Treg and Breg cells develop next to 432 
each other. CD40L+ILC3s may be involved in the maintenance of the immune tolerance in 433 
tonsils by the induction of functional itBreg cells. These cells can contribute to the suppression 434 
of T cell responses both through cell-cell contact via PD-L1, and via secreted IL-10. These 435 
mechanisms may also play a role in immune tolerance-induction during successful sublingual 436 
immunotherapy42-43. 437 
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The absolute numbers of Treg cells and the expression level of Foxp3 in these cells 438 
are dependent on IL-10 production by B cells. The modulation of the Treg cell frequencies in 439 
vivo is exclusively restricted to transitional 2 marginal zone precursor Breg cells in mice44. In 440 
addition, human itBreg cells are able to induce Treg cells in vitro45. Of note, worm infection-441 
induced CD1dhigh IL-10-producing Breg cells can prevent and reverse airway inflammation in 442 
allergized mice by inducing the recruitment of Treg cells to the lung46. Treg cell percentages 443 
were not lower in allergic asthmatics and did not correlate with either ILC3s or itBreg cells, 444 
suggesting that the peripheral blood Treg cell levels may not mirror the immunoregulatory 445 
status, and these cells can be influenced by multiple factors. 446 
Adoptive transfer of itBreg cells can ameliorate allergic airway inflammation and hyper-447 
responsiveness in mouse model of allergic asthma in an IL-10-dependent manner47. The 448 
relative proportion of various Breg cell subsets within B cells was found to be reduced in 449 
allergic diseases (allergic rhinitis48; allergic asthma49), and the frequency of IL-10-producing, 450 
antigen-specific B cells increased after allergen-specific immunotherapy35. 451 
We demonstrated that ILC3s comprised a significantly smaller fraction of tonsillar 452 
lymphocytes in allergic compared to non-allergic patients. The frequency of ILC3s, 453 
expressed as percentage of all CD45+ cells, has been reported to be unaltered in mild 454 
asthmatics (GINA step 1) with confounding allergic rhinoconjunctivitis compared to non-455 
allergic controls50. However, we found significantly reduced circulating ILC3 numbers within 456 
all lymphocytes in highly selected, moderate-to-severe allergic asthmatic patients (GINA step 457 
3 to 4) compared to healthy controls. There was a significant positive correlation between 458 
peripheral blood ILC3 and itBreg cell percentages, and the lower ILC3 levels in allergic 459 
asthmatics were accompanied with lower itBreg cell counts. 460 
It was suggested by mouse models that IL-15 may have a protective role in allergic 461 
diseases51-52. We showed that the CpG- and BAFF-induced IL-15 production is deficient in 462 
tonsillar naïve B cells of allergic patients. This may represent a mechanism that contributes 463 
to the reduction of the size of circulating ILC3 pool. 464 
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Collectively, our experimental results indicate a strong itBreg cell-inducing capacity of 465 
the activated ILC3s, therefore the reduced ILC3 levels may contribute to the insufficient Breg 466 
cell-mediated immune tolerance in various allergic diseases including allergic asthma. 467 
In conclusion, we have described here a novel, innate immunoregulatory function of 468 
CD40L+ILC3s, an activated form of the type 3 innate lymphoid cells. CD40L+ILC3s provide 469 
extrafollicular, T cell-independent B cell help in palatine tonsils and induce immature 470 
transitional Breg cell development. This mechanism may contribute to the maintenance of 471 
immune tolerance to innocuous antigens and become insufficient in allergy. Further 472 
investigation is required to explore the possibility of the therapeutic interventions targeting 473 
ILC3 - B cell interaction in allergic diseases. 474 
 475 
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FIGURE LEGENDS 485 
 486 
FIG 1. Expansion and differentiation of ILC3s 487 
(A) Peripheral blood ILC3s were sorted according to the gating strategy shown in FIG E1A, 488 
expanded with IL-15 for 20 days and analyzed by flow cytometry. CD94+CD40L–c-KitlowcNK 489 
cells, CD94–CD40L–c-KithighILC3s (referred to as CD40L–ILC3s) and CD94–CD40L+c-490 
KithighILC3s (referred to as CD40L+ILC3s) are defined here. These cell populations were 491 
sorted for in vitro experiments. Quadrant statistics in table represents fourteen independent 492 
experiments. 493 
(B) Tonsillar ILC3s were sorted according to the gating strategy shown in FIG E1B, 494 
expanded with IL-15 for 20 days and analyzed by flow cytometry. Tonsillar ILC3s differentiate 495 
mainly into CD40L–ILC3s, and CD40L+ILC3s. These cell populations were sorted for in vitro 496 
experiments. Quadrant statistics in table represents five independent experiments. 497 
(C) Analysis of IL15 mRNA in isolated tonsillar cell populations (*: p<0.05 vs Total TMC, 498 
CD3+, CD19+, and pDC; n=5; except pDC, mDC and Tonsillar Epithel n=3). 499 
(D) NK cell receptor NKp44 expression in circulating ILC3s at isolation, after culture (IL-15, 500 
20 days) and tonsillar ILC3 at isolation, analyzed by flow cytometry (*: p<0.01 vs blood ILC3 501 
at isolation; n=3; except Blood ILC3+IL-15 n=4). 502 
(E) RORC mRNA expression in blood-derived ILC3 subsets defined in A. (*: p<0.05 vs 503 
PBMC and cNK; n=4; except CD40L+ILC3 n=5). 504 
(F) Intranuclear RORγt protein levels in blood ILC3-derived cell subsets defined in A, 505 
analyzed by flow cytometry. (*: p<0.01 vs all other groups; #: p<0.05 vs ISO and cNK; n=3). 506 
(G) IL-22 secretion of blood ILC3-derived cell subsets (defined in A) in response to IL-23 (*: 507 
p<0.05 vs CD40L–ILC3 and cNK; #: p<0.05 vs cNK; n=4). 508 
(H) CD40LG mRNA expression in tonsillar cell subpopulations sorted from fresh tissue 509 
samples (*: p<0.01 vs B cells; n=3). 510 
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 (I) CD40L protein expression on tonsillar ILC3s cultured ex vivo for 36 hours with IL-15, 511 
analyzed by flow cytometry. The number indicates percent CD40L+ cells. One representative 512 
experiment is shown out of two with similar results. 513 
   514 
FIG 2. CD40L+ILC3s support B cell survival, proliferation and IgM production 515 
(A) (B) and (C) Blood-derived CD40L+ILC3s and naïve B cells were cocultured in the 516 
indicated ratios, in the presence of IL-15 and an initial CpG stimulation. Naïve B cells were 517 
sorted according to the gating strategy shown in Fig E6. B cell survival and proliferation were 518 
analyzed on day 12 by flow cytometry. A viability dye, e-450 was used to discriminate 519 
between living and dead cells. Proliferation rate of the B cells was assessed by analysis of 520 
CFSE dilution and calculation of the proliferative index (numbers indicate percent 521 
proliferating cells in parent gate; nd: non-dividing). Statistical analyses of the coculture 522 
experiments are shown on (B) and (C). Cocultures of naïve B+L cells, as well as CD40L–523 
ILC3s and naïve B cells were used as controls. (*: p<0.05 vs 1:15, CD40L–ILC3:B cell 524 
coculture, and B alone; #: p<0.05 vs B alone; †: p<0.05 vs all other groups; n=10-15). 525 
(D) Immunoglobulin production was measured by multiplex bead assay in cell (co)culture 526 
supernatants (day 12; *: p<0.05 vs 1:15, CD40L–ILC3:B cell coculture, B alone and B+L cells 527 
coculture; n=7-10). 528 
 529 
FIG 3. Tonsil-derived CD40L+ILC3s supported B cell survival, proliferation and induced 530 
IL-10-producing B cell differentiation 531 
(A) and (B) Tonsil-derived CD40L+ILC3s and tonsillar naïve B cells were cocultured in 1:1, 532 
1:3 and 1:7 ratios in the presence of IL-15 and an initial CpG stimulation. B cell survival (A) 533 
and B cell proliferation (B) were analyzed on day 12 by flow cytometry. A viability dye, e-450 534 
was used to discriminate between living and dead cells. Proliferation rate of the B cells was 535 
assessed by flow cytometric analysis of CFSE dilution in the dividing cells, and calculation of 536 
the proliferative index. Cocultures of tonsillar naïve B cells + L cells were used as controls. (*: 537 
p<0.05 vs 1:7 and B alone; #: p<0.05 vs B alone; †: p<0.05 vs all other groups; n=5). 538 
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(C) IL-10-producing B cells in tonsil-derived cocultures and B cell alone cultures on day 12, 539 
analyzed by flow cytometry. The plot is gated on all viable cells of a representative tonsil-540 
derived CD40L+ILC3 and B cell (1:3) coculture. IL-10+B cell populations are shown as 541 
percent of all viable CD19+ cells (#: p<0.05 vs B alone; n=3). 542 
 543 
FIG 4. CD40L+ILC3-mediated B cell help is specifically focused on immature 544 
transitional B cells 545 
(A) CD40L+ILC3 and B cell (1:3) coculture on day 12, analyzed by flow cytometry. The first 546 
plot is gated on all viable cells. Immature transitional B (itB) cells were defined as c-Kit–547 
CD19+CD27–IgD+IgM+CD24highCD38highCD1dhigh. IgM single-positive cells were c-Kit–548 
CD19+CD27–IgD–IgM+CD24lowCD38lowCD1dlow (representative of seven independent 549 
experiments). 550 
(B) Proliferation rates of total B cells, itB cells and IgM single-positive B cells in a 551 
CD40L+ILC3 and B cell (1:3) coculture on day 12, analyzed by flow cytometry. (*: p<0.05 vs 552 
B cells and IgM single-positive B cells; n=5). 553 
(C) Flow cytometric comparison of itB cells (defined in A) between CD40L+ILC3 and B cell 554 
cocultures, CD40L–ILC3 and B cell cocultures, B+L cell cocultures and B cells alone cultures. 555 
All dotplots were gated on viable CD19+IgD+IgM+ B cells on day 6. ItB cells are shown in the 556 
graph as percent of all viable CD19+ B cells (#: p<0.05 vs other cultures; *: p<0.01 vs other 557 
cultures; n=5).  558 
(D) ItB cells in freshly isolated TMC samples, analyzed by flow cytometry. First plot is gated 559 
on CD19+CD27– B cells. One representative experiment is shown out of two with similar 560 
results. 561 
Numbers in flow cytometric plots indicate percent cells in parent gate. 562 
 563 
FIG 5. CD40L+ILC3s induce the development of IL-10-secreting B
 
regulatory cells 564 
(A) Cytokine levels in cocultures and B cell alone cultures were measured by multiplex bead 565 
assay on day 6 (*: p<0.05 vs CD40L+ILC3 alone, 1:7 and 1:15 CD40L+ILC3:B cell cocultures, 566 
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CD40L-ILC3:B cell coculture, B+L cells and B alone; #: p<0.05 vs CD40L+ILC3 alone, 1:15 567 
CD40L+ILC3:B cell coculture and B alone; &: p<0.05 vs CD40L+ILC3 alone, 1:15 568 
CD40L+ILC3:B cell coculture, B+L cells and B alone; †: p<0.05 vs all other cultures; n=10-569 
15). 570 
(B) IL-10-producing B cells in cocultures and B cell alone cultures. The plot is gated on all 571 
viable cells. IL-10+B cells are shown as percent of all viable CD19+ B cells (*: p<0.05 vs 1:7 572 
and 1:15 CD40L+ILC3:B cell cocultures, CD40L–ILC3:B cell coculture, B+L cells and B alone; 573 
#: p<0.05 vs CD40L–ILC3:B cell coculture, B+L cells and B alone; †: p<0.05 vs CD40L–574 
ILC3:B cell coculture and B alone; n/a: not available; n=8-13). 575 
(C) Intracellular IL-6 and IL-10 content of B cells in 1:3 CD40L+ILC3:B cell coculture. Plots 576 
are gated on all viable B cells. One representative experiment is shown out of two with 577 
similar results. 578 
(D) Presence of itB cells in IL-10+B cells. The first dotplot is gated on IL-10+B cells developed 579 
in a CD40L+ILC3 and B cell coculture (day 6). The relative abundance of 580 
IgD+IgM+CD24highCD38high itB cells was compared between various cell cultures on day 6 and 581 
12, and shown in the graph. (*: p<0.05 vs all other cultures; n=5). 582 
(E) Comparison of the relative abundance of IgD+IgM+CD24highCD38high itB cells between 583 
CD40L+ILC3 and B cell cocultures, and T cell and B cell cocultures. ItB cells are shown as 584 
percent of all viable CD19+ B cells, and also as percent of all viable CD19+IL-10+B cells (*: 585 
p<0.05 vs CD40L+ILC3 and B cell coculture; day 12; n=2). 586 
(F) Expression of regulatory cell marker PD-L1 on the surface of IL-10+ and IL-10– B cells in 587 
CD40L+ILC3 and B cell cocultures (*: p<0.05 vs IL-10– B cells; day 12; n=2). 588 
(G) Viable B cells were sorted from CD40L+ILC3 cocultures on day 12, and cocultured with 589 
CFSE-labeled PBMC (in 1:5; 1:10 and 1:20 ratio) in the presence of an anti-IL-10-receptor 590 
blocking (αIL-10R) or isotype control (ISO) antibody. Tetanus toxoid (TT)-induced CD4+ T 591 
cell proliferation was analyzed. Freshly sorted autologous Treg (CD3+CD4+IL-7Rα–CD25+) and 592 
PBMC cocultures (in 1:10 and 1:20 ratio), and rhIL-10 (10 ng/mL) treated PBMC were used 593 
as controls (*: p<0.05 vs PBMC; n=2). 594 
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(B-G) Data were analyzed by flow cytometry, numbers in plots indicate percent in parent 595 
gate. 596 
 597 
FIG 6. Role of CD40L in the CD40L+ILC3-B cell interaction 598 
(A) We examined CD40L+ILC3 and B cell, as well as CD40L–ILC3 and B cell cocultures (both 599 
1:3) treated with anti-CD40L neutralizing antibody (αCD40L) or isotype control antibody 600 
(ISO). B cell survival, proliferation and IL-10-producing B cell differentiation were analyzed  601 
(*: p<0.05 vs ISO-treated CD40L+ILC3:B cell cocultures, ns: p>0.05 vs ISO-treated CD40L–602 
ILC3:B cell cocultures; n=3). 603 
(B) Cytokine levels were measured in cell culture supernatants by multiplex bead assay (*: 604 
p<0.05 vs ISO-treated CD40L+ILC3:B cell cocultures; n=3). 605 
(C) Immonoglobulin M (IgM) concentrations were measured in cell culture supernatants by 606 
multiplex bead assay (*: p<0.05 vs ISO-treated CD40L+ILC3 and B cell cocultures; n=3). 607 
(D-F) In order to examine the importance of cell-cell contact, CD40L+ILC3s and B cells were 608 
cocultured in transwell plates. 609 
(D) B cell and CD40L+ILC3 viability was analyzed in normal coculture (Control) and in 610 
Transwell coculture(*: p<0.05 vs Transwell; n=2; e-780: viability dye). 611 
(E) Intracellular IL-6 and IL-10 content of B cells in Control and Transwell CD40L+ILC3s and 612 
B cell cocultures on day 6. Plots are gated on all viable CD19+ B cells. (*: p<0.05 vs 613 
Transwell; n=2). 614 
(F) ItB cells in Control and Transwell CD40L+ILC3s:B cell cocultures on day 6. Dotplots are 615 
gated on viable CD19+IgD+IgM+ B cells. The relative abundance of IgD+IgM+CD24highCD38high 616 
itB cells was compared between Control and Transwell cocultures (ns: p>0.05 vs Control; 617 
n=2). 618 
(A) and (B-G) Data were analyzed by flow cytometry, numbers indicate percent cells in 619 
parent gate. 620 
 621 
FIG 7. The role of BAFF and IL-15 in CD40L+ILC3-B cell interaction 622 
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(A) BAFF expression of CD40L+ILC3s in response to IFN-γ stimulation. One representative 623 
experiment is shown out of two with similar results. 624 
(B) IL15 mRNA expression in B cells in response to coculturing CD40L+ILC3s or irradiated L 625 
cells (*: p<0.05 vs B cells alone and B+L cells; n=2). 626 
(C) Intracellular IL-15 content of B cells in 1:3 CD40L+ILC3:B cell coculture on day 12. Effects 627 
of BAFF-receptor blocking (αBAFFr) or isotype control (ISO) antibody on IL-15 expression. 628 
Histogram is gated on all viable B cells. Percentage of the IL-15+ B cells was analyzed (*: 629 
p<0.05 vs ISO; n=2).  630 
(D) Viability of CD40L+ILC3 in B cell cocultures and alone with or without IL-15 on day 6 (*: 631 
p<0.05 vs CD40L+ILC3 alone without IL-15; CD40L+ILC3 alone n=3-4; CD40L+ILC3 632 
cocultures n=6-8). 633 
(E) The relative abundance of IgD+IgM+CD24highCD38high itB cells was compared between 634 
αBAFFr and ISO treated CD40L+ILC3s and B cell cocultures on day 6. Dotplots are gated on 635 
viable CD19+IgD+IgM+ B cells. (*: p<0.05 vs ISO; n=2). 636 
(F) Naïve B cells were isolated from tonsil tissue, and stimulated with CpG and/or BAFF for 4 637 
days. IL15 mRNA expression were compared between samples of allergic and non-allergic 638 
patients (*: p<0.05 vs Non-allergic; n=4). 639 
(G) Intracellular IL-15 content of tonsillar naïve B cells after 4 days of CpG and BAFF 640 
stimulation. Plots are gated on all viable B cells (*: p<0.05 vs Non-allergic; n=4). 641 
(A), (C), (D), (E), and (G) Data were analyzed by flow cytometry, numbers indicate percent 642 
cells in parent gate. 643 
 644 
FIG 8. Colocalization of ILC3s and IL-10+Breg cells in the regulatory cell niches of 645 
palatine tonsils; interrelation of ILC3s and itBreg cells in allergy. 646 
(A) Immunofluorescence histology of tonsils. RORγt+CD3– ILC3s and CD20+IL-10+Breg cells 647 
are in close contact with each other in vivo. CD3+IL-10+Treg cells are also localized in the 648 
same region of the tissue. The localization of the ILC3s, Breg cells and Treg cells is 649 
demonstrated with a collection of pictures from different sections because the ILC3s are 650 
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relatively rare. Filled arrows: RORγt+CD3– ILC3s; open arrows: CD20+IL-10+Breg cells; 651 
asterisk: CD3+IL-10+Treg cells. Bright-field pictures (BF) are shown in the rightmost column. 652 
Representative isotype control stainings are shown in the lower row. 653 
Representative images of three independent experiments. Scale bar is 20 µm. 654 
(B) Percentage of ILC3s in tonsillar lymphocytes of allergic and non-allergic patients (ILC3s 655 
were gated according to the strategy shown in Fig. E1B; *: p<0.05 Allergic vs Non-allergic). 656 
(C) Percentage of ILC3s in peripheral blood lymphocytes of allergic asthma patients and 657 
healthy controls (ILC3s were gated according to the strategy shown in Fig. E1A; *: p<0.01 658 
Allergic asthma vs Healthy). 659 
(D) Correlation between ILC3 and CD19+IgD+IgM+CD24highCD38highCD1dhighPD-L1+ itBreg cell 660 
percentages in peripheral blood lymphocytes of allergic asthma patients (triangle) and 661 
healthy controls (circle). 662 
  663 
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ONLINE REPOSITORY 
 
MATERIALS AND METHODS 
 
Isolation of cells 
Peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll (Biochrom) density 
gradient centrifugation within 3 hours of sample collection. Tonsil mononuclear cells (TMCs), 
tonsillar myeloid and plasmacytoid DCs (mDCs and pDCs) were isolated as previously 
described by us40. Briefly, single-cell suspensions of TMCs were isolated by mechanical 
disruption. The tissues were chopped and grounded with RPMI 1640 medium (Sigma) 
through a 40 µM mesh. After several washing steps with medium, the cells were purified by 
centrifugation on a Ficoll density gradient. 
For tonsillar T cell and B cell preparation, TMC samples were labeled with magnetic 
microbead-bound anti-CD3 and anti-CD19 antibodies, respectively, and the positive cell 
populations were isolated by immunomagnetic separation. 
Tonsil DCs were isolated from TMCs via negative selection by immunomagnetic 
separation (AutoMACS, Miltenyi Biotec) using magnetic microbead-bound anti-CD3, anti-
CD19, anti-CD16, anti-CD14, and anti-CD326 antibodies in the presence of Fc-receptor-
blocking reagent (Miltenyi Biotec). Tonsil mDCs were obtained from tonsil DCs via positive 
selection by CD1c (BDCA-1)+ dendritic cell isolation kit (Miltenyi Biotec) supplemented in the 
first incubation step with anti-CD11c biotinilated antibody. The negative fraction was used for 
the isolation of tonsil pDCs via positive selection by CD304 (BDCA-4/ Neuropilin-1) 
microbead kit (Miltenyi Biotec). 
Tonsillar epithelial cells were isolated according to a previously described protocolE1. 
Briefly, the epithelium were cut off the tonsil tissue, were cut into pieces of approximately 1-2 
mm and trypsinized for 3 hours at 37°C (Trypsin EDT A 0.05 %, Gibco). Trypsin was 
neutralized using TNS (Lonza) and the cells were filtered through a 40 µm nylon mesh. The 
obtained cells were seeded in 75 cm2 plastic culture flasks and cultured in bronchial epithelial 
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growth medium (Lonza). Medium was changed after 24 hours and every second day from 
then on. Cells were harvested at a confluence of 90 % by trypsinisation. 
Tonsillar T and B cell, DC and epithelial cell samples were used for IL15 mRNA 
measurements. 
For cryopreservation, TMCs were resuspended in freezing medium (10% DMSO and 
45% fetal bovine serum in complete RPMI 1640) and stored in liquid nitrogen until flow 
cytometric measurements, as well as ILC3 and B cell isolations by fluorescence activated 
cell sorting. 
 
Flow cytometry 
For the ILC3 measurements, 2.5 million cells were acquired by flow cytometry. The minimum 
limit was 1 million cells. For readout measurements of the coculture experiments, 20’000-
50’000 cells were measured. 
 
Establishment of CD40L+ILC3 cell line, as well as CD40L+ILC3 and B cell cocultures 
All cell cultures were grown in RPMI 1640 medium supplemented with 1 mM sodium 
pyruvate (Sigma), 1% MEM nonessential amino acids and vitamins (Sigma), 2 mM L-
glutamine (Sigma), 100 U/ml penicillin, 100 µg/ml streptomycin (Sigma), 100 µg/ml 
kanamycin (Gibco) and 10% heat-inactivated FCS (Sigma). Cells were cultured in 96 well 
plates in 500-1000 cells/µL concentration. 
L cells are mouse fibroblasts transfected with human CD40L, and are widely used as 
supporting cells in B cell experiments. L cells express high levels of human CD40L on their 
surface, and also releases soluble CD40L (sCD40L). Irradiated L cells (75 Gy) in 50,000/mL 
concentration were used as controls in our experiments in order to compare the supporting 
characteristics and performance of an artificial, highly optimized coculturing cell (L cell) to a 
biologically relevant cell type (CD40L+ILC3). For T and B cell cocultures CD3+CD4+ T cells 
were sorted from the second blood sample of the same donor. 
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Proliferation and suppression assays 
B cell proliferation was analyzed on (co-)culture day 12 by flow cytometric detection of 
carboxyfluorescein diacetate succinimidyl ester (CFSE; Invitrogen) dilution. Proliferative 
index is the median number of divisions the B cells have passed through since the beginning 
of the experiment. For ILC3 proliferation assay, we used Celltrace Violet (Molecular Probes), 
and analyzed on the same way. Cells were stimulated with IL-15, (10 ng/mL; from 
PeproTech). In suppression assay rhIL-10 (10 ng/mL from PeproTech) were used in the 
control wells. Autologous CD3+CD4+CD25+IL-7Rα– regulatory T cells were sorted and used 
for control conditions in suppression assays. 
 
Analysis of cytokine production, intracellular staining 
Blood-derived CD40L+ILC3s, CD40L–ILC3s and cNK cells were cultured with IL-23 (50 
ng/mL, 24h) for the IL-22-production assays; and CD40L+ILC3s were cultured with IFN-γ (0.1 
µg/mL, 2 days) for the BAFF expression experiments (all human recombinant cytokines were 
from PeproTech). IL-22 production of the ILC3s and cNK cells (in response to IL-23) was 
measured after 6 h of phorbol myristate acetate (PMA; 25 ng/ml; Sigma) and ionomycin (1 
µg/mL; Sigma) stimulation with ELISA (PeproTech). Tonsil-derived naïve B cells were 
stimulated with CpG (1 µM) and or BAFF (2 µg/mL) for 4 days in order to induce IL-15 
production. 
Cytofix/Cytoperm Fixation and Permeabilization Kit (Beckton Dickinson) were used for cell 
permeabilization and intracellular staining procedure both for the staining of cytokines (IL-10, 
IL-6, IL-15) and for the other intracellular stainings (TLR-9, Granzyme B, Perforin). For the 
intracellular IL-10, IL-6 and IL-15 staining, cells were stimulated with PMA (25 ng/ml; Sigma) 
and ionomycin (1 µg/mL; Sigma) for 6 h in the presence of brefeldin A (10 µg/ml; Sigma) for 
the final 2 h. For intranuclear transcription factor (RORγt) staining in blood-derived 
CD40L+ILC3s, CD40L–ILC3s and cNK cells a Fix/Perm Buffer Set and a corresponding Cell 
Staining Buffer (Biolegend) were used. Data were acquired on Galios (Beckman Coulter) 
flow cytometer, and were analyzed with Kaluza software (Beckman Coulter). 
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Analysis of cytokine and immunoglobulin production 
Production of cytokines (IL-10, IL-1ra, IL-6, sCD40L) and IgM were measured in cell culture 
supernatants by multiplex cytometric bead-based immunoassays (Bio-Plex system, Bio-
Rad). Supernatants of various cultures were harvested on day 6 for the cytokine, and on day 
12 for the immunoglobulin measurements. Spontaneous cytokine and immunoglobulin 
secretion of the cells after the initial (day 1) CpG stimulation were detected, and it was not 
boosted by any further stimulation. 
 
Quantitative real-time RT-PCR 
Total RNA was extracted with RNeasy Micro kit (Qiagen) according to the manufacturer’s 
instructions. cDNA was synthesized using oligo-dT and reverse transcription reagents 
(Thermo Scientific) according to manufacturer’s protocols. SYBR Green/ROX qPCR master 
mix (Bio-Rad) was used for amplification of the PCR products. All primers were designed by 
us (listed in Supplementary Table 1.; purchased from Microsynth). Quantitative RT-PCR 
analysis was carried out on ABI Prism 7900HT instrument (Applied Biosystems), the relative 
gene expression levels were calculated using the comparative Ct (∆∆Ct) method. All results 
were normalized to the expression of EEF1A1 (encoding elongation factor 1α). 
 
Immunofluorescence histology 
The preparation, staining procedure and acquisition of frozen human palatine tonsil tissue 
sections were previously described by us41. Briefly, palatine tonsil tissues were embedded in 
Optimal Cutting Temperature (OCT) compound (Tissue-Tek, Sakura Finetek), frozen in liquid 
nitrogen-cooled 2-methylbutane (Fluka), and stored at -80°C until cryosections were cut by 
an HM 500 OM Cryostat microtome (Mikrotom). Paraformaldehyde-fixed cryosections (7 µm) 
were sequentially incubated with the primary antibody, an Alexa Fluor dye-conjugated goat 
secondary antibody, and blocked with the isotype control antibody corresponding to the 
primary antibody. These staining cycle were repeated with all subsequent primary antibodies 
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during the staining protocol. We developed a 4 color immunnofluorescence staining for the 
detection RORγt+CD3– ILC3s and CD20+IL-10+ Breg cells together in the same specimen. The 
detection of ILC3s based on a previously reported approachE2. 
The following antibodies were used for the detection of ILCs in the tissue: anti-RORγt 
(AFKJS-9;  eBioscience) anti-CD161 (DX12; Beckton Dickinson), anti-CD3 (CD3-12; Abd 
Serotec), anti-CD40L (40804; RnD), anti-CD20 (EP459Y; Epitomics), anti-IL-10 (polyclonal 
goat, RnD) and corresponding isotype control antibodies (from the same sources or Dako). 
Alexa Fluor dye-conjugated, species and isotype specific secondary antibodies (Invitrogen) 
were used for detection of the bound primary antibodies. 
Tissue sections were mounted with ProLong Gold antifade reagent with or without 
DAPI (Invitrogen). Images were captured using a Leica TSC SPE confocal microscope with a 
ACS APO 63X 1.3 OIL objective. Data were acquired by Leica Application Suite Advance 
Fluorescence 2.4.1 software (Leica Microsystems). Brightness, contrast and color balance of 
the pictures were adjusted in Imaris 7.7 image analysis software (Bitplane). Image panels 
were composed in Photoshop CS2. The general histology of palatine tonsils was 
demonstrated by staining of the sections with Hematoxylin and Eosin. 
 
Antibodies and viability dye 
The following antibodies were used for flow cytometric measurements and sorting 
experiments: Alexa Fluor 488-conjugated anti-CD24 (ML5), anti-IL-7Rα (anti-CD127; 
A019D5), fluorescein isothiocyanate (FITC)-conjugated anti-IL-6 (MQ2-13A5), phycoerythrin 
(PE)-conjugated anti-BAFF (T7-241), anti-CD138 (DL-101), anti-CD94 (DX22), anti-IgD (IA6-
2), anti-IL-6 (MQ2-13A5), PE/Dazzle594-conjugated anti-CD38 (HIT2) peridinin chlorophyll 
protein-cyanine 5.5 (PerCP-Cy5.5)-conjugated anti-CD3 (UCHT1), anti-CD19 (HIB19), anti-
CD20 (2H7), anti-CD14 (HCD14), anti-CD11c (B-ly6), anti-CD34 (581), anti-CCR6 
(TG7/CCR6), anti-IgM (MHM-88), PE-indotricarbocyanine (Cy7)-conjugated anti-CD1d 
(51.1), anti-c-Kit (anti-CD117; 104D2), anti-CD38 (HIT2), allophycocyanin (APC)-conjugated 
anti-CD161 (HP-3G10), anti-CD94 (DX22), Alexa Fluor 647-conjugated anti-IL-10 (JES3-
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9D7), Alexa Fluor 700-conjugated anti-CD19 (HIB19), APC-Cy7-conjugated anti-CD19 
(HIB19), anti-CD40L (anti-CD154; 24-31), IgM (MHM-88), Pacific Blue (PB)-conjugated anti-
CD56 (MEM-188), Brillant Violet (BV) 421-conjugated anti-CD24 (ML5), anti-c-Kit (anti-
CD117; 104D2), BV510-conjugated anti-CD19 (HIB19) and isotype-matched control 
antibodies conjugated to PE, PB, Alexa Fluor 700, APC-Cy7, BV421 and BV510 (MOPC-21), 
conjugated to FITC, PE (RTK2071), and conjugated to BV421 (MOPC-173; all from 
BioLegend); FITC-conjugated anti-IL-7Rα (anti-CD127; HIL-7R-M21), anti-PD-L1 (CD274; 
MIH1), anti-IgD (IA6-2), PE-conjugated anti-CD3 (HIT3A), anti-CD40L (anti-CD154; TRAP1), 
anti-CD27 (M-T271), PerCP-Cy5.5-conjugated anti-CD3 (UCHT1), anti-CD14 (M5E2), anti-
CD56 (B159), APC-conjugated anti-CD161 (DX12), anti-CD40L (anti-CD154; TRAP1), Alexa 
Fluor 647-conjugated anti-NKp44 (p44-8.1), and isotype-matched control antibodies 
conjugated to FITC, Alexa Fluor 488, PE, PerCP-Cy5.5, PE-Cy7, Alexa Fluor 647, APC 
(MOPC-21; all from Beckton Dickinson); PE-conjugated anti-RORγt (AFKJS-9), anti-
Granzyme B (GB11), anti-Perforin (dG9), anti-CD1d (51.1), anti-TLR-9 (eB72-1665), and 
isotype-matched control antibodies conjugated to PE (rat IgG2a - eBR2a and mouse IgG2a - 
eBMG2b; all from eBioscience); PE-conjugated anti-CD56 (N901 (NHK-1)), anti-IgD (IADB6), 
PE-Texas Red-conjugated anti-CD4 (SCFCI12T4D11), APC-AF750-conjugated anti-CD3 
(UCHT1), and isotype-matched control antibodies conjugated to PE-Texas Red (2T8-2F5), 
APC-AF750 (679.1Mc7; all from Beckman Coulter); PE-conjugated and APC-conjugated 
anti-IL-15 (34559), purified anti-APRIL (670840; all from R&D Systems); Alexa Fluor 647-
conjugated goat anti-mouse IgG secondary antibody (polyclonal, from Invitrogen); Alexa 
Fluor 488-conjugated anti-IgG and Alexa Fluor 647-conjugated anti-IgA (policlonal goat 
antibodies, both from Jackson ImmunoResearch). 
Fixable viability dyes (eFluor 450 and eFluor 780, eBioscience; termed as e-450 and 
e-780) was used for dead cell discrimination. We used two different viability dyes to fit them 
in the best way to various multicolor ILC3 and B cell flow cytometry panels. 
For functional experiments the following neutralizing and isotype control antibodies 
were used: purified (low endotoxin, azide free) anti-CD40L (anti-CD154; 24-31), anti-IL-10R 
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(3F9) and isotype matched control antibodies (MOPC-21, RTK2758; all from Biolegend); 
anti-BAFFr/TNFRSF13C and normal IgG control polyclonal goat antibodies (both from R&D 
Systems). 
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FIGURES 
 
 
FIG E1. 
Type 3 innate lymphoid cells (ILC3s) in peripheral blood and tonsil tissue 
(A) Flow cytometric analysis of the ILC3s in peripheral blood mononuclear cells (PBMCs). 
First plot is gated on lymphocytes identified by size and complexity. Lineage markers (Lin) 
were CD3, CD19, CD20, CD14, CD34, CD11c, CD94. Numbers indicate percent cells in 
parent gate. ILC3s defined as IL-7Rα+CD4–Lin–CD56–CD161+c-Kit+ cells. Data are 
representative of more than fifty independent experiments. 
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(B) Flow cytometric analysis of the ILC3s in tonsillar mononuclear cells (TMCs). First plot is 
gated on lymphocytes identified by size and complexity. Data are representative of twelve 
independent experiments. 
(A) and (B) ILC3s were sorted from PBMC and TMC samples with FACSAria II (Beckton 
Dickinson) according to the gating strategy shown on A and B, respectively. 
(C) RORC mRNA expression of freshly isolated blood ILC3s. Total PBMCs and sorted cNK 
cells were controls (*: p<0.05 vs PBMC and cNK; mean ± SEM; n=5, one-way ANOVA with 
Bonferroni post hoc test).  
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FIG E2. 
The new expansion strategy with IL-15 results in ILC3s clearly distinct from ILC2s, 
ILC1s and cNK cells. 
(A-D) CD40L+ILC3s did not show the characteristics of ILC1, ILC2 or cNK cells. 
(A) and (B) Lack of GATA3 (A) and TBX21 (B) mRNA expression of CD40L+ILC3s sorted 
according to the gating strategy shown on Fig. 1A. TBX21 gene is encoding T-bet. Total 
PBMCs and in vitro differentiated Th2 (A) and Th1 (B) cells were used as controls (*: p<0.01 
vs PBMC and CD40L+ILC3). 
(C) CD40L+ILC3s did not express GZMB and PRF1 mRNA encoding the cytotoxic enzymes 
granzyme B and perforin, respectively. CD40L+ILC3s and cNK cells (from ILC3 cultures) 
were sorted according to the gating strategy shown on Fig. 1A. Freshly sorted peripheral 
blood cNK cells were used as controls (*: p<0.05 vs PBMC and CD40L+ILC3). 
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(D) Intracellular granzyme B and perforin proteins were detected by flow cytometry. 
CD40L+ILC3s and cNK cells (from ILC3 cultures) were sorted according to the gating 
strategy shown on Fig. 1A. Freshly isolated, blood-derived CD56lowCD3– cNK cells were 
used as positive controls (*: p<0.05 vs ISO and CD40L+ILC3; MFI: median fluorescence 
intensity). 
Mean ± SEM; (B-E) n=3-5, one-way ANOVA with Bonferroni post hoc test.  
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FIG E3. 
RORγt+ ILC3s are residing at the interface between T and B cell areas in the tonsils, 
and are in close connection with B cells 
Immunofluorescence histology of tonsils. The connection of RORγt+CD3– ILC3s and B cells 
is demonstrated with a collection of pictures from different sections because the ILC3s are 
rare cells and scattered around the interface of the T and B cell areas in tonsils. Filled 
arrows: RORγt+CD3– ILC3s. Open arrows: CD20+ B cells. Representative isotype control 
stainings are shown in the lower row. In lower left corner the light microscopic structure of the 
tonsils is shown with Hematoxylin and Eosin staining. The B cell follicles (“B”) are surrounded 
by the T cell area (“T”). The black quadrant approximately shows the field, which is magnified 
on immunofluorescence images. 
Representative images of three independent experiments. Scale bar is 20 µm.  
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FIG E4. 
CD40L+ ILCs are residing at the interface between T and B cell areas in the tonsils 
Immunofluorescence histology of tonsils. Arrows show CD161+ CD40L+ and CD20– ILCs on 
the border of the T cell - B cell areas in the tonsil tissue. CD40L+ILCs are close to CD20+ B 
cells in tonsils. 
Representative images of three independent experiments. Scale bar is 20 µm.  
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FIG E5. 
TLR-9 and CD40L in ILC3s 
(A) Intracellular toll-like receptor 9 (TLR-9) expression in CD40L+ILC3s or CD40L–ILC3s 
analyzed by flow cytometry (n=5). 
(B) Soluble CD40L (sCD40L) concentrations were measured in supernatants of 
CD40L+ILC3s alone, CD40L–ILC3s alone and L cells alone cultures by multiplex bead assay, 
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with or without initial CpG stimulation. Equal numbers of CD40L+ILC3s or CD40L–ILC3s were 
seeded, and the supernatants were harvested on day 5 (*: p<0.01 vs CD40L+ILC3 without 
CpG stimulation and all CD40L–ILC3 cultures; ns: p>0.05 vs L cells with CpG stimulation; 
one-way ANOVA with Bonferroni post hoc test; n=5). 
(C) The stability of CD40L expression on CD40L+ILC3s or CD40L–ILC3s after 8 days of 
culture with or without CpG stimulation, analyzed by flow cytometry. Data are representative 
of 2 independent experiments.  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
17 
 
 
 
FIG E6. 
Naïve B cells isolation strategy and purity check of the sorted cells 
(A) Sorting strategy for circulating naïve B cells isolation. These cells were used for the 
blood-derived ILC3 and B cell cocultures. First plot is gated on peripheral blood lymphocytes 
identified by size and complexity (PBMCs were used as a sample). Naïve B cells were 
defined as CD19+CD27–IgG–IgA– cells. We used the same isolation strategy for tonsillar 
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naïve B cell isolation also.  Tonsillar naïve B cells were isolated from TMC samples and used 
for the tonsil-derived ILC3 and B cell coculture experiments. 
(B) The sorted naïve B cell purity was examined by flow cytometry. The isolated naïve B 
cells were highly pure CD19+CD27–IgD+IgM+CD38+ B cells. 
Data are representative of fifteen independent experiments.  
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FIG E7. 
The role of BAFF in CD40L+ILC3 – B cell interaction 
(A-E) B cell survival (A), proliferation (B), IL-10-producing B cell development (C) were 
analyzed by flow cytometry; cytokine (D) and IgM production (E) were measured by multiplex 
bead assay in cell culture supernatant of 1:3 CD40L+ILC3s:B cell cocultures treated with 
blocking αBAFFr or isotype control (ISO) antibody.  Flow cytometric and IgM measurements 
were performed on day 12, and cytokine measurements on day 6 (ns: p>0.05 vs ISO treated 
cocultures; n=2). 
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FIG E8. 
Colocalization of ILC3s and IL-10+Breg cells in the regulatory cell niches of palatine 
tonsils; interrelation of  ILC3s itBreg and Treg cells in allergic asthma patients. 
(A) Immunofluorescence histology of tonsils. Representative, low magnification overview 
picture of an interfollicular region, close to a T cell area. Colors corresponding to the same 
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antigens as in Fig. 8A. There are numerous CD20+IL-10+ Breg cells (open arrows) and 
CD3+IL-10+ Treg cells (asterisk) close to an ILC3 (filled arrow). 
(B) Percentage of CD19+IgD+IgM+CD24highCD38highCD1dhighPD-L1+ itBreg cells in tonsillar 
lymphocytes of allergic and non-allergic patients (*: p<0.05 Allergic asthma vs Healthy). 
(C) Percentage of CD3+CD4+IL-7Rα–CD25+ Treg cells in peripheral blood lymphocytes of 
allergic asthma patients and healthy controls (ns: p>0.05). 
(D) Interrelation of ILC3 and Treg cell percentages in peripheral blood of allergic asthma 
patients (triangle) and healthy controls (circle). 
(E) Interrelation of ItBreg and Treg cell percentages in peripheral blood of allergic asthma 
patients (triangle) and healthy controls (circle). 
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TABLE E1. 
Sequences of real-time qPCR primers 
mRNA Primer Sequences (5’-3’) 
EEF1A1 Forward CCA CCT TTG GGT CGC TTT GCT GT 
 Reverse TGC CAG CTC CAG CAG CCT TCT T 
RORC Forward CCT GGC AAA GCT GCC ACC CA 
 Reverse AGC GGC TTG GAC CAC GAT GG 
IL15 Forward TCT GAT CAT CCT AGC AAA CAA CAG 
 Reverse CCA GTT CCT CAC ATT CTT TGC AT 
GATA3 Forward GCG GGC TCT ATC ACA AAA TGA 
 Reverse GCT CTC CTG GCT GCA GAC AGC 
TBX21 Forward GAT GCG CCA GGA AGT TTC AT 
 Reverse GCA CAA TCA TCT GGG TCA CAT T 
GZMB Forward TTC CTT TAA GGG GGA CTC TGG 
 Reverse GAG GCA TGC CAT TGT TTC GT 
PRF1 Forward TGA TGC CAC CAT TCC AGG AG 
 Reverse GAG AAG GAT GCC CAG GAG GA 
CD40LG Forward AAG CCA GTT TGA AGG CTT TGT 
 Reverse GAG GAT TCT GAT CAC CTT TTT GCA T 
 
